openPR Logo
Press release

Novalung receives CE mark for iLA activve®

03-17-2011 12:00 PM CET | Health & Medicine

Press release from: Novalung GmbH

iLA activve - the new all-rounder for extrapumonary lung support

iLA activve - the new all-rounder for extrapumonary lung support

Novalung receives CE mark for iLA activve®

With the new all-rounder for extrapulmonary lung support Novalung GmbH is the only company worldwide offering the complete portfolio for both pumpless and pump-driven lung support.

Novalung announces receiving CE mark approval for their new pump-driven iLA activve® lung support system. It will be launched in Europe with immediate effect.

Respiratory support with iLA activve® enables a treatment environment with awake, mobile patients instead of sedated patients on invasive mechanical ventilation that causes further damage to the lung and other organs. The iLA activve® is thus a major step towards replacing invasive mechanical ventilation.

Different patient populations and types of lung failure place varying demands on optimal respiratory support. To cover all extrapulmonary support needs with one system platform, the iLA activve® has been developed as a flexible all-rounder. The iLA activve® with veno-venous cannulation covers the full range of respiratory support, from highly effective carbon dioxide elimination to complete oxygenation. Core elements are the iLA Membrane Ventilator®, the only gas exchanger specifically designed for long-term respiratory support, and the iLA activve® pump which surpasses all previously available blood pumps in its performance, broad range of blood flow, and blood protection characteristics.

The iLA activve® system has been specifically configured to allow patients to move about during respiratory support. Therefore all necessary components are mounted on an easily movable trolley. Furthermore the iLA Membrane Ventilator® and the iLA activve® pump are height-adjustable via a quick-release handle. “This allows physicians, respiratory therapists and nurses to adjust the system to the patient’s individual needs, whether the patient is in bed, sits up or even walks”, explains Dr. Georg Matheis, Managing Director of Novalung.

The range of applications of the iLA Membrane Ventilator® technology has broadened substantially. While severe acute lunge failure (ARDS) was the typical indication in the early days, today exacerbations of chronic lung disease (COPD) comprise a growing application of the iLA Membrane Ventilator®. Novalung will launch several additional products for the iLA activve® platform throughout this year.

Background information

Objective: replacing the invasive mechanical ventilation

Novalung‘s mission is the creation of new Solutions for Lung Failure using artificial lungs that breathe for the patient outside the body. Instead of placing patients in an artificial coma so that they can tolerate mechanical ventilation, Novalung products enable the patients to experience their treatment while awake, mobile and breathing easily. The innovative technologies open the door for physicians and nurses to this vision. The overall objective is to replace damaging invasive mechanical ventilation.

Novalung GmbH
Founded in 2003, the German company Novalung GmbH operates on a highly international level in order to establish new solutions for lung failure. These advanced technologies from Germany and the U.S. were brought into the company and developed further.
From the outset Novalung has focused on high-quality development and production “Made in Germany“. Cutting-edge technologies are employed in Novalung’s medtech production facility in the manufacture in particular of the iLA Membrane Ventilator® and NovaPort® vascular access cannulas, both of which have been used to help treat thousands of patients.

The privately funded Novalung GmbH is a fast growing medical technology company based in the area of Heilbronn/Germany and with a subsidiary on the campus of the University of Michigan in Ann Arbor, USA.

Please send us a copy of your imprint.


Mrs Franziska Preissing
Head of Marketing
Tel.: +49 7131 27 06 130
Fax: +49 7131 27 06 230

Novalung GmbH
Im Zukunftspark 1
74076 Heilbronn

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Novalung receives CE mark for iLA activve® here

News-ID: 166882 • Views: 5993

More Releases from Novalung GmbH

NovaPort twin, the Newest Double-Lumen Cannula, Approved
Novalung adds the unique double-lumen cannula to its expanding portfolio of products for the extrapulmonary treatment of lung failure. Now only a single cannula is required instead of two. Novalung announced today that it has received approval for the new NovaPort twin® double-lumen cannula, which is now available for clinical use. The NovaPort® twin cannula was specifically designed for veno-venous vascular access for the iLA activve® system - the Allrounder for
Novalung and Medos start cooperation
Due to the acquisition of Medos Medizintechnik AG by the private equity fund Zukunftsfonds Heilbronn (“Future Fund of Heilbronn”) the company will cooperate closely in the future with Novalung GmbH, which is expected to strengthen both medical device companies. The Zukunftsfonds Heilbronn (zfhn) announced that it has acquired Medos Medizintechnik AG from Ventizz Capital Partners Advisory AG. The purchase agreement was signed on January 7, 2011. With this
Josef Bogenschuetz joins Novalung as Managing Director
Novalung GmbH prepares for further growth with former Maquet CEO. As of January 1, 2011, Josef Bogenschütz and Dr. Georg Matheis are joint Managing Directors of Novalung GmbH. Bogenschütz will be specifically responsible for Research & Development, Manufacturing, Quality Management and Finance. This addition underscores the company’s focus on the ongoing and efficient expansion of its portfolio of innovative products designed to replace invasive mechanical ventilation. Nicholas L. Strout remains responsible
Novalung GmbH continues expansion into Scandinavia
The world’s first pumpless lung assist device, the iLA Membrane Ventilator®, now exclusively available in Sweden and Norway through Vingmed Group. Novalung GmbH, the German manufacturer of the world’s leading therapeutic system for extrapulmonary lung support, has signed exclusive agreements with Vingmed Svenska AB and Vingmed AS for distribution of the iLA Membrane Ventilator® in Sweden and Norway, respectively. Dr. Torsten Rinne, Medical Director of Novalung GmbH, noted: “We have seen

All 5 Releases

More Releases for Membrane

Membrane Bioreactor Market 2017-2023 | Key Players GE Water and Process Technolo …
The membrane bioreactor is the technology for wastewater treatment industries, which is witnessing greater adoption in the global market. The market includes the study of various types of configurations, products, applications and geographic analysis. The membrane bioreactor technology is more advanced than conventionally activated sludge method of wastewater management. The technology is efficient due to lower operational and maintenance cost. The market is driven due to increased utilization of the
Membrane Microfiltration Market 2018 - 2028 | By Membrane Type ( PES Membrane F …
Membrane Microfiltration Market: Value and Forecast The global membrane microfiltration market is expected to expand at a CAGR of 7.8% in revenue terms over the forecast period 2018–2028. The global membrane microfiltration market is expected to be dominated by Western Europe with a 22.3% revenue share in 2018. Membrane Microfiltration Market: Product Outlook In water treatment systems, microfiltration membranes help in removing small particles and solids such as iron (rust), manganese (rust), clay, silt and
Membrane Technology Market | Market Growth Analysis 2019
Transparency Market Research (TMR) has recently published a market study on the global membrane technology market, projecting the market to exhibit a CAGR of 9.10% during the period from 2014 to 2019 and reach a market value of US$10.8 bn by the end of the forecast period.The report, titled “Membrane Technology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019”, states that the worldwide membrane
Breathable Membrane Market : Industry Analysis 2024
Breathable membranes are semi-porous films or sheets, which allow the exchange of water vapor while preventing liquid water from permeating through. These membranes prevent water from seeping into the roof structure, while providing cold and warm ventilation. Breathable membranes are primarily used in the building & construction industry; they are used as underlay for various types of roofs such as slated pitched roofs and tiled roofs. Large amount of water
United States Photosensory Membrane Market Report 2017
Summary This report studies sales (consumption) of Photosensory Membrane in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering Company 1 Company 2 Company 3 Company 4 Company 5 Company 6 Company 7 Market Segment by States, covering California Texas New York Florida Illinois Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into Type I Type II Split by applications, this report focuses on sales, market share
Global Membrane Switches Sales Market Report 2017
This report studies sales (consumption) of Membrane Switches in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Molex(US) XYMOX(US) Douglas Corporation(US) Fujikura(JP) Human E&C(KOR) Human E&C(KOR)